The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
In the research published in BMC Surgery, fecal elastase-1 (FE-1) test emerged as the most frequently utilized diagnostic ...
The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback